Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/ 10.14670/HH-18-404


Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Hall, Benjamin | - |
dc.contributor.author | George, Jonathan G. | - |
dc.contributor.author | Allen, Scott P. | - |
dc.date.accessioned | 2023-02-10T09:02:53Z | - |
dc.date.available | 2023-02-10T09:02:53Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Histology and Histopathology Vol. 37, nº3 (2022) | es |
dc.identifier.issn | 0213-3911 | - |
dc.identifier.issn | 1699-5848 | - |
dc.identifier.uri | http://hdl.handle.net/10201/128325 | - |
dc.description.abstract | Adenosine deaminase (ADA) is a purine metabolism enzyme that catalyses the breakdown of adenosine and deoxyadenosine. The enzyme is important in several cellular processes, including the innate immune response and cellular differentiation, and it is also an important enzyme for the maintenance of brain homeostasis, in part due to its regulation of adenosine. Aberrant regulation of ADA enzyme activity has been linked to several neurodegenerative diseases and diseases that can result in neurological impairment. However, the mechanisms behind altered ADA regulation and how this leads to the development of neurological dysfunction are poorly characterised. This review summarises the current research on ADA and its role and regulation in disease pathology, with a focus on the central nervous system (CNS) and the neurodegenerative disease, amyotrophic lateral sclerosis (ALS) | es |
dc.format | application/pdf | es |
dc.format.extent | 24 | es |
dc.language | eng | es |
dc.publisher | Universidad de Murcia, Departamento de Biologia Celular e Histiologia | es |
dc.relation | Sin financiación externa a la Universidad | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Adenosine deaminase | es |
dc.subject | Central nervous system | es |
dc.subject | Pathology | es |
dc.subject | Severe combined immunodeficiency | es |
dc.subject | Amyotrophic lateral sclerosis | es |
dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología | es |
dc.title | Adenosine deaminase, not immune to a mechanistic rethink in central nervous system disorders? | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.doi | https://doi.org/ 10.14670/HH-18-404 | - |
Aparece en las colecciones: | Vol.37, nº3 (2022) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Hall-37-189-212-2022.pdf | 4,48 MB | Adobe PDF | ![]() Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons